hydrazinocurcumin

Hydrazinocurcumin is a **synthetic derivative of curcumin** with improved water solubility, stability, and cellular permeability compared to curcumin, leading to enhanced bioavailability and pharmacological effects[2][6]. It exhibits **potent anti-cancer and anti-angiogenic activity**, acting through **inhibition of STAT3 (signal transducer and activator of transcription 3) phosphorylation** and associated downstream oncogenic pathways, as well as **activation of the p38 mitogen-activated protein kinase (MAPK) pathway**[1][2][3][6]. Preclinical studies indicate superior efficacy and pro-apoptotic activity against cancer cells—especially breast and liver (hepatocellular) carcinomas—compared to curcumin and even 5-fluorouracil in some models[1][6]. Hydrazinocurcumin also inhibits endothelial cell proliferation and angiogenesis at low concentrations[3], and can reprogram tumor-associated macrophages toward a tumor-inhibiting phenotype in animal models[5].

Other names

hydrazinocurcuminHZCHC